Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Akorn will acquire generics company Hi-Tech for $640 million in cash, or $43.50 per Hi-Tech share. The price is
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury